Akebia Therapeutics was founded in 2007 and is headquartered in Cambridge, US

Akebia Therapeutics has an office in Cambridge

Cambridge, US (HQ)

1100 245 First St

USD

## Net income (Q1, 2017) | (44.5 m) |

## EBIT (Q1, 2017) | (45 m) |

## Market capitalization (21-Jul-2017) | 541.3 m |

## Cash (31-Mar-2017) | 87.3 m |

Akebia Therapeutics's current market capitalization is $541.3 m.

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## R&D expense | 25.4 m | 43 m | 115.8 m |

## General and administrative expense | 12.5 m | 18.5 m | 22.2 m |

## Operating expense total | 37.9 m | 61.5 m | 138 m |

## EBIT | (37.9 m) | (61.5 m) | (136.5 m) |

## Interest expense | 206 k | 510 k | |

## Interest income | 206 k | 510 k | 901 k |

## Net Income | (37 m) | (60.7 m) | (135.7 m) |

USD | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|

## R&D expense | 7.5 m | 7.2 m | 15.8 m | 20.2 m | 30.9 m | 31.2 m | 60 m |

## General and administrative expense | 3.4 m | 3.7 m | 3.9 m | 5.8 m | 5.3 m | 4.9 m | 5.8 m |

## Operating expense total | 10.9 m | 10.9 m | 19.7 m | 26 m | 36.2 m | 36.2 m | 65.8 m |

## EBIT | (10.9 m) | (10.9 m) | (19.7 m) | (26 m) | (36.2 m) | (36.2 m) | (45 m) |

## Interest expense | 96 k | 116 k | 139 k | 234 k | |||

## Interest income | 96 k | 116 k | 139 k | 234 k | 270 k | 219 k | 435 k |

## Net Income | (10.7 m) | (10.7 m) | (19.5 m) | (25.8 m) | (35.8 m) | (36.3 m) | (44.5 m) |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 32.8 m | 49.8 m | 187.3 m |

## Accounts Receivable | 48 k | 933 k | |

## Inventories | 1.5 m | 2.6 m | 2.2 m |

## Current Assets | 110.5 m | 141 m | 296.3 m |

## PP&E | 209.9 k | 540 k | 2.6 m |

## Total Assets | 111 m | 142.9 m | 300.2 m |

## Accounts Payable | 2 m | 2.3 m | 2 m |

## Current Liabilities | 6.9 m | 11.9 m | 114.3 m |

## Total Liabilities | 232.1 m | ||

## Additional Paid-in Capital | 205 m | 292.8 m | 365.3 m |

## Retained Earnings | (100.7 m) | (161.4 m) | (297.1 m) |

## Total Equity | 104.1 m | 131 m | 68.1 m |

## Financial Leverage | 1.1 x | 1.1 x | 4.4 x |

USD | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|

## Cash | 27.9 m | 76.2 m | 66.7 m | 43.4 m | 46.2 m | 65.8 m | 87.3 m |

## Accounts Receivable | 74 k | 48 k | 14 k | ||||

## Current Assets | 102.7 m | 155 m | 158.8 m | 219.5 m | 192.5 m | 165.1 m | 255.1 m |

## PP&E | 404 k | 398 k | 479 k | 629 k | 1.8 m | 2.7 m | 2.9 m |

## Total Assets | 103.5 m | 155.7 m | 159.6 m | 221.4 m | 195.6 m | 169.1 m | 259.3 m |

## Accounts Payable | 4.3 m | 2.4 m | 5.3 m | 2.4 m | 5.1 m | 8.5 m | 15.1 m |

## Current Liabilities | 8.8 m | 5.9 m | 14.2 m | 13.4 m | 20.9 m | 26.1 m | 133.5 m |

## Additional Paid-in Capital | 206.1 m | 272 m | 287.1 m | 355.1 m | 356.2 m | 360 m | 372.5 m |

## Retained Earnings | (111.4 m) | (122.1 m) | (141.5 m) | (187.2 m) | (223 m) | (259.3 m) | (341.7 m) |

## Total Equity | 94.6 m | 149.8 m | 145.4 m | 167.8 m | 133.3 m | 100.7 m | 30.6 m |

## Financial Leverage | 1.1 x | 1 x | 1.1 x | 1.3 x | 1.5 x | 1.7 x | 8.5 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (37 m) | (60.7 m) | (135.7 m) |

## Depreciation and Amortization | 49.4 k | 96 k | 296 k |

## Accounts Receivable | 87 k | ||

## Inventories | (773 k) | (1 m) | 428 k |

## Accounts Payable | 4.1 m | 231 k | (274 k) |

## Cash From Operating Activities | (27.5 m) | (52.4 m) | 57.9 m |

## Purchases of PP&E | (229 k) | (414 k) | (2.7 m) |

## Cash From Investing Activities | (65.4 m) | (13.7 m) | 12.7 m |

## Cash From Financing Activities | 104.4 m | 83.1 m | 66.9 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (10.7 m) | (10.7 m) | (19.5 m) | (25.8 m) | (35.8 m) | (36.3 m) | (44.5 m) | ||

## Accounts Receivable | 114 k | 57 k | 74 k | 48 k | 14 k | ||||

## Accounts Payable | 1.5 m | 3 m | 4.3 m | 2.4 m | 5.3 m | 2.4 m | 5.1 m | 8.5 m | 15.1 m |

Y, 2017 | |
---|---|

## Financial Leverage | 8.5 x |